Related Experiment Video
Updated: Jul 29, 2025

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Penicillin-Susceptible Streptococcus pneumoniae Meningitis in Adults: Does the Ceftriaxone Dosing Matter?
Samuel Raemy1, Carlo Casanova1, Rossella Baldan1
1Institute for Infectious Diseases, University of Bern, 3001 Bern, Switzerland.
Abstract:
The recommended empiric ceftriaxone dosing regimen for acute bacterial meningitis in adults is 2 g every 12 h. After penicillin-susceptible Streptococcus pneumoniae is isolated as a causative microorganism, the ceftriaxone dose may be continued or reduced to a single dose of 2 g every 24 h, per institutional preference. There is no clear guidance that indicates the superiority of one regimen over the other. The objective of this study was to evaluate the susceptibility of S. pneumoniae in the cerebral spinal fluid (CSF) of patients with meningitis and the relationship between ceftriaxone dose and clinical outcomes. We identified 52 patients with S. pneumoniae meningitis with positive CSF cultures who were treated at the University Hospital, Bern, Switzerland, over a 19-year period. We collected clinical and microbiological data for evaluation. Broth microdilution and Etest methods were performed to test penicillin and ceftriaxone susceptibility. All isolates were susceptible to ceftriaxone. Ceftriaxone was empirically used in 50 patients, with a starting dosing regimen of 2 g every 24 h in 15 patients and 2 g every 12 h in 35 patients. In 32 patients started on a twice-daily regimen (91%), doses were reduced to once daily after a median of 1.5 (95% CI 1-2) days. The overall in-hospital mortality was 15.4% (n = 8), and 45.7% of patients reported at least one sequela of meningitis at the last follow-up (median 375, 95% CI 189-1585 days). We found no statistical difference in outcome between the 2 g every 24 h and the 2 g every 12 h ceftriaxone dosing regimens. A ceftriaxone total daily dose of 2 g may be associated with similar outcomes to a 4 g total daily dose, provided that the causative organism is highly susceptible to ceftriaxone. The persistence of neurological and infection sequelae at the last follow-up underscores the need for optimal treatment of these complex infections.
Insights
For bacterial meningitis caused by susceptible Streptococcus pneumoniae, a daily 2g ceftriaxone dose is as effective as 4g daily. This finding supports potentially lower ceftriaxone dosing for meningitis treatment.
Area of Science:
- Infectious Diseases
- Neurology
- Pharmacology
Background:
- Acute bacterial meningitis requires effective antibiotic treatment.
- Ceftriaxone is a recommended empiric therapy for bacterial meningitis.
- Dosing strategies for ceftriaxone in Streptococcus pneumoniae meningitis vary, with no clear superiority established for higher doses.
Purpose of the Study:
- To evaluate ceftriaxone susceptibility in Streptococcus pneumoniae from cerebrospinal fluid (CSF) in meningitis patients.
- To determine the relationship between ceftriaxone dosing regimens (2g every 24h vs. 2g every 12h) and clinical outcomes.
Main Methods:
- Retrospective analysis of 52 patients with S. pneumoniae meningitis over 19 years.
- Collected clinical and microbiological data.
- Assessed penicillin and ceftriaxone susceptibility using broth microdilution and Etest.
Main Results:
- All S. pneumoniae isolates were susceptible to ceftriaxone.
- No statistical difference in in-hospital mortality or sequelae was observed between the 2g/24h and 2g/12h ceftriaxone regimens.
- A total daily dose of 2g ceftriaxone showed similar outcomes to 4g daily in highly susceptible cases.
Conclusions:
- A reduced daily dose of ceftriaxone (2g) may be sufficient for treating S. pneumoniae meningitis when isolates are highly susceptible.
- Further research is needed to optimize treatment and reduce long-term sequelae of meningitis.
- Clinical decisions on ceftriaxone dosing should consider organism susceptibility and patient outcomes.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Factors Affecting Drug Response: Overview
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...